

Global Evolution of Clinical Trials and Pharmacy Activities developed in a Central Portuguese Hospital from 2016 to 2023

Marina Lobo Alves^{1,2}, Margarida Falcão^{1,2,7}, Tânia Laranjeira^{1,2}, Ana Mirco^{1,2}, Liliana Calixto^{1,2}, Sara Maia^{2,3,4}, Miguel Viana Baptista^{2,5,6}, Fátima Falcão^{1,2,7}

1. Serviços Farmacêuticos da Unidade de Saúde Local Lisboa Ocidental (ULSLO); 2. Centro Clínico Académico de Lisboa (CCAL), 3. NOVA CRU, NOVA Medical School (NMS), 4. Comprehensive Health Research Center (CHRC), 5. Centro de Investigação e Inovação Clínica (CIIC), ULSLO, 6. NOVA Medical School (NMS), 7. Faculdade de Farmácia da Universidade de Lisboa

Background and Importance

Without effective treatment, an aging population, new diseases, and rising antimicrobial resistance pose challenges. Clinical trials (CTs) are essential for proving drug efficacy and safety, facilitating access to innovative therapies, and advancing clinical research in Portugal. Legislation mandates Pharmaceutical Services' participation in CTs, ensuring safety, responsibility, transparency and traceability.

Aim and Objectives

Analyze clinical trials evolution in ULSLO's Pharmaceutical Services over the past 8 years.

Methods


A descriptive and retrospective study was performed between January 2016 and December 2023. Data was obtained from an Excel database and a medication management software (Glintt®). A descriptive analysis methodology was performed.

Results

Clinical Trials in numbers (2016-2023)

19 approved new CTs/ year

64 CTs monitoring visits/ year




TOP YEAR 2023

37 new CTs
92 ongoing trials
26 departments

Top 4 Departments 2023


Neurology
Rheumatology
Nephrology
Oncology




Results

CLINICAL TRIAL PHASES

■ Phase II ■ Phase III ■ Phase IV ■ Other Phases



Pharmaceutical Activities in numbers (2016-2023)



Sponsors (2023):

- Pharmaceutical industry: 90% (n=83)
- Investigator initiative studies: 10% (n=9)

Conclusion and Relevance

Clinical studies are a key strategic area for health development in Portugal. The Clinical Innovation and Research Service promotes good clinical practice and supports study implementation, with oncology and neurology as areas of excellence. Highly qualified clinical research teams, including hospital pharmacists, ensure an efficient experimental drug circuit in compliance with legislation. The data aligns with indicators in the annual report from official regulatory entities in Portugal.

References:

- <https://www.infarmed.pt/web/infarmed/entidades/medicamentos-uso-humano/ensaios-clinicos/estatisticas>
- <https://apifarma.pt/indicadores/ensaios-clinicos>

Contacts: tlaranjeira@ulslo.min-saude.pt

